Filter by patients with: All

What is MS Phase 3 Daclizumab Study DECIDE?

Category: Others

false

See also: Daclizumab

NCT01064401 is a double-blind, randomized, parallel-group, monotherapy, active-control study to determine the efficacy and safety of daclizumab high yield process (DAC HYP) versus Avonex® (interferon β 1a) in patients with relapsing-remitting MS. Other study names are 205MS301, 2009-012500-11.

See patients taking MS Phase 3 Daclizumab Study DECIDE

See all 3 patients that have used MS Phase 3 Daclizumab Study DECIDE
Last updated:
There are no evaluations for MS Phase 3 Daclizumab Study DECIDE.